Wos İndeksli Yayınlar Koleksiyonu

Permanent URI for this collectionhttps://hdl.handle.net/11727/4807

Browse

Filters

20203

Settings

Author: search.filters.author.Kilicdag, Esra Bulgansearch.filters.applied.f.rights: search.filters.rights.info:eu-repo/semantics/closedAccess

Search Results

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    Pregnancy and immune thrombocytopenia: New trends Response
    (2020) Kalayci, Hakan; Durdag, Gulsen Dogan; Baran, Safak Yilmaz; Simsek, Seda Yuksel; Alemdaroglu, Songul; Ozdogan, Serdinc; Kilicdag, Esra Bulgan; 0000-0002-5064-5267; 0000-0002-0942-9108; 0000-0003-4335-6659; AAI-9594-2021; AAK-8872-2021; AAI-8400-2021; AAK-7016-2021; ABF-6439-2020
  • No Thumbnail Available
    Item
    Role of prophylactic and therapeutic red blood cell exchange in pregnancy with sickle cell disease: Maternal and perinatal outcomes
    (2020) Baran, Safak Yilmaz; Kozanoglu, Ilknur; Korur, Asli; Durdag, Gulsen Dogan; Kalayaci, Hakan; Alemdaroglu, Songul; Asma, Suheyl; Kilicdag, Esra Bulgan; Boga, Can; 0000-0002-0942-9108; 0000-0002-5086-5593; 0000-0002-5268-1210; 0000-0003-4335-6659; 0000-0001-5335-7976; 0000-0002-5064-5267; 0000-0002-8902-1283; 0000-0001-5874-7324; 0000-0002-9680-1958; 32797735; ABF-6439-2020; AAK-8872-2021; AAD-5616-2021; AAD-6222-2021; AAE-1241-2021; AAI-8400-2021; AAI-7831-2021; AAI-9594-2021; AAD-5542-2021
    Background and Aim The incidence of fetomaternal complications during pregnancy is high for women with sickle cell disease (SCD), which is the most common hematologic genetic disorder worldwide. Prophylactic red blood cell exchange (pRBCX) has been shown to be efficient, safe, and feasible for preventing complications. The aim of this study was to observe maternal, perinatal, and neonatal outcomes of pregnancies in which pRBCX was. Method This was a single-center, retrospective, cross-sectional study, which recruited 46 consecutive adult pregnant women with SCD between January 2012 and June 2019. Obstetric features, SCD-related complications, and fetomaternal outcomes were compared between the 27 patients who received prophylactic exchange and the 19 who did not (therapeutic exchange was performed in 7 and was not performed in 12 cases). Results Painful crises, preeclampsia, and preterm birth rates were significantly higher in the group that did not receive prophylactic exchange (control group;P= .001,P= .024, andP= .027, respectively). There was one maternal mortality in the control group (P= .41). Incidence of adverse fetal or maternal complications was significantly higher in the control group (P= .044 andP= .007, respectively). Conclusions Our center's experience over a 7.5-year period, as described above, demonstrates that pRBCX in SCD affects the course of pregnancy positively by ameliorating negative fetomaternal outcomes.
  • No Thumbnail Available
    Item
    Does abnormal ductus venosus pulsatility index at the first-trimester effect on adverse pregnancy outcomes?
    (2020) Baran, Safak Yilmaz; Kalayci, Hakan; Durdag, Gulsen Dogan; Yetkinel, Selcuk; Arslan, Alev; Kilicdag, Esra Bulgan; 0000-0002-2165-9168; 0000-0002-5064-5267; 0000-0002-0942-9108; 0000-0003-4444-0027; 0000-0001-5874-7324; 32623067; AAL-1530-2021; AAI-9594-2021; AAK-8872-2021; V-1112-2019
    Aim: The ductus venosus pulsatility index for veins (DV PIV) has become a popular marker of the first-trimester scan. The aim of this study is to search for any difference between groups with normal and abnormal DV PIV values in terms of adverse pregnancy outcomes. Methods: We retrospectively evaluated 556 women whose first-trimester scan was performed. The ductus venosus pulsatility indices were examined at singleton pregnancies between 11 and 14 weeks of gestation. Patients were categorized as Group-I with normal DV PIV (DV PIV >= 0.73, <= 1.22) and as Group-II with abnormal DV PIV. Group-II was subgrouped as Group-IIA which composed of patients with DV PIV < 0.73 and as Group-IIB with DV PIV > 1.22. Results: There were 451 subjects in Group-I and 105 subjects in Group-II (Group-IIA = 32 and Group-IIB 73). The comparisons between major groups revealed a statistically significant increase about miscarriage (p = 0.002), stillbirth (p < 0.001), small for gestational age (p = 0.033), low birth weight (p < 0.001), fetal growth restriction (p = 0.048), and major congenital heart defect (p=<0.001) in Group-II. This difference is mainly due to Group-IIB. There is no difference in preterm delivery, preeclampsia and gestational diabetes between Group I and II. Conclusion: Routinely monitoring DIV PIV as a first-trimester screening should provide valuable information regarding adverse pregnancy outcomes such as miscarriage, stillbirth, small for gestational age, low birth weight, fetal growth restriction and major congenital heart defect. (C) 2020 Elsevier Masson SAS. All rights reserved.